The Comparative Effectiveness between Branded Generic Atorvastatin (Lipostat®) and Authorized Generic Atorvastatin (Xarator®): A Prospective Cohort Study

{"title":"The Comparative Effectiveness between Branded Generic Atorvastatin (Lipostat®) and Authorized Generic Atorvastatin (Xarator®): A Prospective Cohort Study","authors":"","doi":"10.35755/jmedassocthai.2023.10.13898","DOIUrl":null,"url":null,"abstract":"Background: An authorized generic drug has identical ingredients as the brand-name drug but marketed as a generic version by the innovator company with a lower cost. A branded generic drug is an imitation of the brand-name medication whose patent has expired. The active elements of a branded generic medicine are the same as those of the original drug, however the inactive ingredients may differ. Objective: To assess the effectiveness of the branded generic atorvastatin (Lipostat®), compared to the authorized generic atorvastatin (Xarator®) in decreasing low density lipoprotein cholesterol (LDL-C) levels. Materials and Methods: The present study was a prospective cohort study that included patients who had been taking the authorized generic atorvastatin (Xarator®) 40 mg once daily for at least three months. The authorized generic atorvastatin (Xarator®) was switched to branded generic atorvastatin (Lipostat®) 40 mg once daily for the next three months. Blood chemistry including lipid profile were evaluated before and three months after the transition from Xarator® to Lipostat®. Results: Of the 61 patients, mean age was 67.0±9.9 years, and 45 (73.7%) were male. The two most common comorbidities included coronary artery disease in 80.3% and hypertension in 60.7%. At three months after switching to branded generic atorvastatin, the mean total cholesterol changed from 133.6±28.8 to 130.0±25.8 mg/dL, the triglyceride changed from 123.3±78.3 to 115.6±70.1 mg/dL, and the LDL-C changed from 68.8±24.1 to 65.5±20.3 mg/dL, thus, they were not significantly different compared to the baseline. There were also no significant differences in adverse events between Lipostat® and Xarator®. Conclusion: Branded generic atorvastatin (Lipostat®) is as effective as the authorized generic atorvastatin (Xarator®) in lowering LDL-C levels. Keywords: Atorvastatin; Authorized generic drug; Branded generic atorvastatin; Low-density lipoprotein cholesterol; High-density lipoprotein cholesterol; Statin","PeriodicalId":484667,"journal":{"name":"JOURNAL OF THE MEDICAL ASSOCTATION OF THAILAND","volume":"8 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JOURNAL OF THE MEDICAL ASSOCTATION OF THAILAND","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35755/jmedassocthai.2023.10.13898","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: An authorized generic drug has identical ingredients as the brand-name drug but marketed as a generic version by the innovator company with a lower cost. A branded generic drug is an imitation of the brand-name medication whose patent has expired. The active elements of a branded generic medicine are the same as those of the original drug, however the inactive ingredients may differ. Objective: To assess the effectiveness of the branded generic atorvastatin (Lipostat®), compared to the authorized generic atorvastatin (Xarator®) in decreasing low density lipoprotein cholesterol (LDL-C) levels. Materials and Methods: The present study was a prospective cohort study that included patients who had been taking the authorized generic atorvastatin (Xarator®) 40 mg once daily for at least three months. The authorized generic atorvastatin (Xarator®) was switched to branded generic atorvastatin (Lipostat®) 40 mg once daily for the next three months. Blood chemistry including lipid profile were evaluated before and three months after the transition from Xarator® to Lipostat®. Results: Of the 61 patients, mean age was 67.0±9.9 years, and 45 (73.7%) were male. The two most common comorbidities included coronary artery disease in 80.3% and hypertension in 60.7%. At three months after switching to branded generic atorvastatin, the mean total cholesterol changed from 133.6±28.8 to 130.0±25.8 mg/dL, the triglyceride changed from 123.3±78.3 to 115.6±70.1 mg/dL, and the LDL-C changed from 68.8±24.1 to 65.5±20.3 mg/dL, thus, they were not significantly different compared to the baseline. There were also no significant differences in adverse events between Lipostat® and Xarator®. Conclusion: Branded generic atorvastatin (Lipostat®) is as effective as the authorized generic atorvastatin (Xarator®) in lowering LDL-C levels. Keywords: Atorvastatin; Authorized generic drug; Branded generic atorvastatin; Low-density lipoprotein cholesterol; High-density lipoprotein cholesterol; Statin
品牌仿制阿托伐他汀(Lipostat®)和授权仿制阿托伐他汀(Xarator®)的有效性比较:一项前瞻性队列研究
背景:授权的仿制药具有与品牌药相同的成分,但由创新公司以较低的成本作为仿制药销售。品牌仿制药是对专利过期的品牌药的仿制。品牌仿制药的活性成分与原药相同,但非活性成分可能不同。目的:评估品牌仿制药阿托伐他汀(Lipostat®)与授权仿制药阿托伐他汀(Xarator®)在降低低密度脂蛋白胆固醇(LDL-C)水平方面的有效性。材料和方法:本研究是一项前瞻性队列研究,纳入了服用授权仿制药阿托伐他汀(Xarator®)40 mg每日一次至少3个月的患者。授权仿制药阿托伐他汀(Xarator®)转换为品牌仿制药阿托伐他汀(Lipostat®)40 mg,每天一次,持续三个月。从Xarator®到Lipostat®转换前和转换后三个月评估血液化学(包括血脂)。结果:61例患者平均年龄67.0±9.9岁,男性45例(73.7%)。两种最常见的合并症包括冠状动脉疾病(80.3%)和高血压(60.7%)。改用阿托伐他汀3个月后,平均总胆固醇由133.6±28.8 mg/dL变为130.0±25.8 mg/dL,甘油三酯由123.3±78.3变为115.6±70.1 mg/dL, LDL-C由68.8±24.1变为65.5±20.3 mg/dL,与基线比较无显著差异。在不良事件方面,Lipostat®和Xarator®也没有显著差异。结论:品牌仿制药阿托伐他汀(Lipostat®)在降低LDL-C水平方面与授权仿制药阿托伐他汀(Xarator®)同样有效。关键词:阿托伐他汀;获批仿制药;阿托伐他汀仿制药;低密度脂蛋白胆固醇;高密度脂蛋白胆固醇;他汀类药物
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信